IMMUTEP LIMITED - AMER

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

19 11 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

15 11 2021 08:00:03 提供 Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

15 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

09 11 2021 08:05:00 提供 Nasdaq GlobeNewswire

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

09 11 2021 08:00:04 提供 Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

02 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 10 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report & Appendix 4C

28 10 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep to Present Phase II TACTI-002 Data at SITC 2021

01 10 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

29 9 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

28 9 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

21 9 2021 08:38:03 提供 Nasdaq GlobeNewswire

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

01 9 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

31 8 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

27 8 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 8 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 7 2021 08:00:03 提供 Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 7 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 6 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 6 2021 08:00:00 提供 Nasdaq GlobeNewswire